This programme has been initiated in 2018 with the support of ISITE-BFC, FEDER and Innovation Regional Fund.
Diaclone is the leader of this research program in partnership with the Franche-Comte Burgundy University, the CGFL and the CHU of Besançon. Pharm’image is in charge of the project coordination.
This project represents a major scientific challenge through the identification of novel imaging biomarkers of immnotherpay efficacy in oncology, based on the clinical expertise, new bioconjugation technologies of antibody fragments and preclinical imaging platform of the partners.
These developments will be valorized with novel patents, scientific publications of the results, new commercial opportunities for Diaclone’s antibodies, and the preclinical proof of concept of new biomarkers for further clinical application.
Scientific symposium ISITE-BFC #1 – 13.10.2020 – Dijon
